Itolizumab
Itolizumab is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is a first-in-class drug that selectively targets the CD6 molecule, a pan-T cell marker involved in co-stimulation, adhesion, and maturation of T cells. Itolizumab was developed by Biocon, a biopharmaceutical company based in India.
Mechanism of Action[edit]
Itolizumab binds to the CD6 molecule, which is present on the surface of T cells. By binding to CD6, itolizumab inhibits the proliferation and activation of T cells, which are involved in the pathogenesis of autoimmune diseases.
Clinical Uses[edit]
Itolizumab has been approved for the treatment of moderate to severe plaque psoriasis in India. It is also being studied for its potential use in other autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.
Side Effects[edit]
The most common side effects of itolizumab include nausea, fatigue, headache, and infusion reactions. Serious side effects may include infections and allergic reactions.
Development and Approval[edit]
Itolizumab was developed by Biocon and received approval from the Drug Controller General of India (DCGI) in 2013 for the treatment of plaque psoriasis. In 2020, it received emergency use approval from the DCGI for the treatment of cytokine release syndrome in moderate to severe COVID-19 patients.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
